All News

An analysis shows that oral semaglutide significantly lowers the risk of heart failure (HF) outcomes in patients with type 2 diabetes and a history of HF.

A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.

New reports reveal rising insurance costs, senior drug savings, and cancer care inequities, showing how policy and partnerships shape health outcomes.

Individuals can use these 5 ways to minimize their cancer risk during National Cancer Prevention Month and beyond.

A new patient decision aid uses a staged approach to help adults with moderate to severe atopic dermatitis choose systemic treatments effectively.

OCEANIC-STROKE shows asundexian cuts recurrent ischemic stroke risk across noncardioembolic subtypes without increasing major bleeding risk.

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase.

Major and minor risk factors, including early eczema and delayed food introduction, shape childhood food allergy risk, a review found.

Longer diabetes duration was associated with a significantly increased risk of pancreatic cystic neoplasms.

Ricciuti explains why advanced adoptive cell therapies require major infrastructure, toxicity management, and strong academic–community collaboration.

A new psoriasis severity tool called G2-PASE showed a strong correlation with PASI, potentially offering a simpler assessment for clinical practice.

Study finds breast cancer survival gaps tied to historical redlining narrowed over time, though newer therapies may be widening disparities again.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Epcoritamab delivers lasting 3-year remissions in relapsed large B-cell lymphoma, with over half of complete responders staying progression-free.

Jordan Karlitz, MD, explains the rise in CRC-related deaths in younger adults, stressing the need for earlier screening and symptom awareness.

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

CBT for insomnia, especially digital CBT, often saves costs vs no treatment or drugs, while the cost-effectiveness evidence for hypersomnia remains absent.

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables.

Vishal A. Patel, MD, shares skin cancer prevention tips, highlighting sun-smart habits, risk-based screening, and at-home early detection.

Anasuya Gunturi, MD, PhD, explains how academic–community partnerships help deliver complex oncology services closer to home.

The FDA approved Optune Pax, a first-of-its-kind portable device delivering tumor-treating fields for locally advanced pancreatic cancer treatment at home.

Findings highlight strong overall performance but reveal variability among disaggregated Asian ethnic groups.

New bipartisan legislation would ban parent companies from owning insurers or PBMs and providers or management services organizations simultaneously.

As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.

As pharmaceutical R&D policies evolve, the authors argue it is crucial to embed American patient values in reimbursement deliberations and frameworks.

OCEANIC-STROKE trial data show asundexian cuts ischemic stroke across subtypes with no rise in major bleeding, which could reshape antithrombotic choices.

Many older HFpEF patients appear to have CKD from aging and obesity; visceral adiposity drives kidney risk more than intrinsic damage or low eGFR.

A stronger effect on neovascular age-related macular degeneration (nAMD) was found with faricimab vs aflibercept.